5AM Ventures puts $4.9M into pre-funded warrants as Camp4 closes $50.1M placement, lifting its stake to 9.9%
CAMP has more than doubled off its 52-week low of $1.32.
Summary
5AM Ventures disclosed a $4.9 million purchase of pre-funded warrants in Camp4's recent $50.1 million private placement, increasing its beneficial ownership to 9.9% — a strong vote of confidence from the company's largest venture investor.
Key Events · Ownership and Investor Activity · CAMP
-
5AM Ventures VII Buys $4.9M in Pre-Funded Warrants
During the second closing of Camp4's private placement, 5AM Ventures VII, L.P. purchased 3,179,558 pre-funded warrants at $1.5299 each, for a total of $4.9 million. The warrants are exercisable for one share of common stock at $0.0001 per share, are immediately exercisable, and never expire.
-
5AM Group Ownership Rises to 9.9%
Post-closing, the 5AM Ventures group beneficially owns 6,313,434 shares (including pre-funded warrants and vested options), representing 9.9% of Camp4's outstanding common stock. Andrew J. Schwab holds 9.99% and Kush Parmar holds 9.98%, both capped by a 9.99% beneficial ownership blocker in the warrants.
-
Placement Terms: $1.53/Share and Pre-Funded Warrants
The second closing involved the sale of 10,756,498 shares at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 each, plus 39,306 shares to management and co-founders at $1.65 per share. The pre-funded warrants have a nominal exercise price of $0.0001 and are immediately exercisable.
-
Follows Positive SYNGAP1 Regulatory News
The investment comes less than two weeks after Camp4 received Australian clearance to begin a Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, and months after positive preclinical data showed improved seizure control.
Analysis · CAMP · Life Sciences
In the second closing of Camp4's private placement, 5AM Ventures VII, L.P. acquired 3.18 million pre-funded warrants for $4.9 million, pushing the 5AM group's total beneficial ownership to 9.9%. The warrants carry a nominal exercise price of $0.0001, are immediately exercisable, and never expire — effectively a direct equity stake with a 9.99% blocker. Coming just days after Australian clearance for a Phase 1/2 trial of CMP-002, this filing underscores the venture capital firm's continued conviction in Camp4's SYNGAP1 program.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.4% of the 1981 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAMP was trading at $4.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $208.2M. The 52-week trading range was $1.32 to $7.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.